

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Information for the public

Published: 20 December 2017

www.nice.org.uk

Ribociclib (Kisqali), with an aromatase inhibitor, is available on the NHS. It is a possible option for adults who have locally advanced or metastatic breast cancer that:

- is hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative and
- has not been treated with endocrine therapy before.

If you are not eligible for ribociclib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS website may be a good place to find out more about breast cancer [in women](#) and [men](#).

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0333 207 0300
- [Breast Cancer Care](#), 0808 800 6000
- [Macmillan Cancer Support](#), 0808 808 0000
- [Cancer Research UK Patient Information](#), 0808 800 4040

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2762-3